On July 31, 2025, LENZ Therapeutics announced that the U.S. Food and Drug Administration (FDA) has approved VIZZ (aceclidine ophthalmic solution) 1.44 percent, making it the first and only aceclidine-based eye drop approved to improve near vision in adults with presbyopia. Wilson Sonsini Goodrich & Rosati serves as outside general counsel for LENZ and advised the company on general corporate and IP matters related to the FDA’s approval of VIZZ.

Samples of VIZZ are anticipated in the United States as early as October 2025, with commercial product to be broadly available by mid-Q4 2025. Direct-to-eye care professional sales and marketing activities will be initiated immediately. Aceclidine, the sole active ingredient in VIZZ, is a new chemical entity in the United States and its FDA approval marks a global first in the treatment of presbyopia, a condition that impacts approximately 128 million adults in the U.S.

The Wilson Sonsini team advising LENZ was led by Dan Koeppen, Ben Capps, Mike Hostetler, and Ian Edvalson.

For more information, please see LENZ Therapeutics’ news release and visit www.VIZZ.com.